Osteosarcoma

Journal of Bone and Mineral Research

Volumn 25, Issue 4, 2010, Pages 683-691

  Gorlick, Richard ^a   Khanna, Chand ^b  

^a YESHIVA UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 12; CISPLATIN; DICKKOPF 1 PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

AGE DISTRIBUTION; ANGIOGENESIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL FEATURE; DNA DAMAGE; DRUG MEGADOSE; FAMILIAL CANCER; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; LUNG METASTASIS; MESENCHYMAL STEM CELL; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NONHUMAN; OSSIFICATION; OSTEOSARCOMA; PATHOGENESIS; REVIEW; TREATMENT FAILURE;

AGE OF ONSET; ANIMALS; BONE AND BONES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DOGS; DRUG RESISTANCE, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LI-FRAUMENI SYNDROME; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA;

EID: 77953433833     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.77     Document Type: Review

References (83)

1. Janeway K, Gorlick R, Bernstein M. Osteosarcoma. In: Orkin S, Fisher D, Look A, Lux S, Ginsburg D, Nathan D, eds. Oncology of Infancy and Childhood. Philadelphia: Saunders Elsevier; 2009:871-910.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-441. (Pubitemid 39014554)
3. Gorlick R, Toretsky J, Marina N, et al. Bone tumors. In: Kufe D, Pollock R, Weichselbaum R, et al., eds. Cancer Medicine, 6th ed., Vol. 2. Hamilton, Ontario, Canada: BC Decker; 2003:2383-2406.
4. Marina N, Gorlick R, Bielack S. Pediatric osteosarcoma In: Carroll W, Finlay J, eds. Cancer in Children and Adolecents. Sudbury, MA: Jones and Bartlett; 2010:383-394.
5. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008;10:315-327.
6. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009;9:511-523.
7. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9:5442-5453. (Pubitemid 37499462)
8. Foley PJ, Scheri RP, Smolock CJ, Pippin J, Green DW, Drebin JA. Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice. J Gastrointest Surg. 2008;12:1452-1458.
9. Chow WH, Devesa SS, Blot WJ. Colon cancer incidence: recent trends in the United States. Cancer Causes Control. 1991;2:419-425.
10. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229-234.
11. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531-1543.
12. Miura M, Chen XD, Allen MR, et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 2004;114:1704-1713. (Pubitemid 40385526)
13. Schwab JH, Antonescu CR, Athanasian EA, et al. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008;466:1318-1322.
14. Kaste SC, Fuller CE, Saharia A, et al. Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features. Pediatr Blood Cancer. 2006;47:152-162. (Pubitemid 44025247)
15. Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008;22:1662-1676. (Pubitemid 351846845)
16. Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A. 2008;105:11851-11856.
17. Lin PP, Pandey MK, Jin F, et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009;30:1789-1795.
18. Mohseny AB, Szuhai K, Romeo S, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219:294-305.
19. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007;25:371-379. (Pubitemid 46232791)
20. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer. 2009;101:2064.
21. Cai Y, Mohseny AB, Karperien M, et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2009;220:24-33.
22. Lee N, Smolarz AJ, Olson S, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer. 2007;97:1552-1559. (Pubitemid 350175854)
23. Thomas DM. Wnts, bone and cancer. J Pathol. 2010;220:1-4.
24. Chen K, Fallen S, Abaan HO, et al. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer. 2008;51:349-355.
25. Guo Y, Zi X, Koontz Z, et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 2007;25:964-971. (Pubitemid 47046444)
26. Leow PC, Tian Q, Ong ZY, et al. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs. 2009.
27. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res. 2008;466:2039-2045.
28. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009;28:3197-208.
29. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009;119:837-851.
30. Zanotti S, Canalis E. Notch and the skeleton. Mol Cell Biol. 2010;30:886-896.
31. Engin F, Bertin T, Ma O, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009;18:1464-1470.
32. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008;14:2962-2969.
33. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6:339-351.
34. Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666-4673.
35. Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle. 2006;5:1751-1755. (Pubitemid 44435317)
36. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009;41:1452-1462.
37. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-284.
38. Khanna C. Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep. 2008;10:350-358.
39. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007;109:813-819. (Pubitemid 46333523)
40. Quan GM, Choong PF. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006;25:707-713.
41. Yin D, Jia T, Gong W, et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008;33:253-259.
42. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-186. (Pubitemid 38524889)
43. Ren L, Hong SH, Cassavaugh J, et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2009;28:792-802.
44. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406-2411. (Pubitemid 40490152)
45. Wan X, Kim SY, Guenther LM, et al. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene. 2009;28:3401-3411.
46. Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007;26:567-578. (Pubitemid 350115108)
47. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-2567. (Pubitemid 40569454)
48. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-211.
49. Miura K, Uniyal S, Leabu M, et al. Chemokine receptor CXCR4-beta1 integrin axis mediates tumorigenesis of osteosarcoma HOS cells. Biochem Cell Biol. 2005;83:36-48. (Pubitemid 40637965)
50. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994;54:2803-2807. (Pubitemid 24173778)
51. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992;84:966-971.
52. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 2007;13:1322-1330. (Pubitemid 46424074)
53. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist. 2009;14:83-91.
54. Corso S, Migliore C, Ghiso E, et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene. 2008;27:684-693. (Pubitemid 351158907)
55. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
56. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995;10:739-749.
57. Scotlandi K, Baldini N, Oliviero M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996;149:1209-1219. (Pubitemid 26337240)
58. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003;17:1162-1164.
59. MacEwen EG, Kutzke J, Carew J, et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003;20:421-430. (Pubitemid 37108428)
60. Engelman JA. Targeting PI3K signalling in cancer: opportunities. challenges and limitations Nat Rev Cancer. 2009;9:550-562.
61. Robert F, Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets. 2009;13:1279-1293.
62. Hwang M, Perez CA, Moretti L, Lu B. The mTOR signaling network: insights from its role during embryonic development. Curr Med Chem. 2008;15:1192-1208. (Pubitemid 351997807)
63. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006;8:394-401. (Pubitemid 43830746)
64. Mahalingam D, Mita A, Sankhala K, et al. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009;10:937-949.
65. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8:3646-3657.
66. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748-1754.
67. Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65:8142-8150.
68. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
69. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928-940.
70. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008;14:4572-4583.
71. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32-40. (Pubitemid 46142757)
72. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147-156. (Pubitemid 351161319)
73. Paoloni MC, Tandle A, Mazcko C, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One. 2009;4:e4972.
74. Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008;7:3-9.
75. Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008;14:6387-6395.
76. Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact. 2002;2:570-572.
77. Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents Targeting Prostate Cancer Bone Metastasis. Anticancer Agents Med Chem. 2009;
78. O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res. 2003; (415 Suppl): S100-S104.
79. Brown SA, Guise TA. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol. 2007;4:310-320.
80. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 2008;34 (Suppl 1): S19-S24.
81. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009;
82. Bartsch R, Steger GG. Role of denosumab in breast cancer. Expert Opin Biol Ther. 2009;9:1225-1233.
83. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7:18-22.